Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Zoetis Inc (ZTS) USD0.01

Sell:$128.45 Buy:$128.47 Change: $1.06 (0.83%)
Market closed |  Prices as at close on 11 October 2019 | Switch to live prices |
Sell:$128.45
Buy:$128.47
Change: $1.06 (0.83%)
Market closed |  Prices as at close on 11 October 2019 | Switch to live prices |
Sell:$128.45
Buy:$128.47
Change: $1.06 (0.83%)
Market closed |  Prices as at close on 11 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

Contact details

Address:
10 Sylvan Way
PARSIPPANY
07054-3825
United States
Telephone:
+1 (973) 8227000
Website:
https://www.zoetis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ZTS
ISIN:
US98978V1035
Market cap:
$61.35 billion
Shares in issue:
477.56 million
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Juan Alaix
    Chief Executive Officer, Director
  • Glenn David
    Chief Financial Officer, Executive Vice President
  • Roxanne Lagano
    Executive Vice President, Chief Human Resources Officer and Communications
  • Andrew Fenton
    Executive Vice President and Chief Digital and Technology Officer
  • Heidi Chen
    Executive Vice President, General Counsel, Corporate Secretary
  • Catherine Knupp
    Executive Vice President, President - Research and Development
  • Clinton Lewis
    Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
  • Kristin Peck
    Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
  • Roman Trawicki
    Executive Vice President, President of Global Manufacturing and Supply

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.